Free Cardiology CME

  • FREE

    Free Cardiology CME from Pri-Med® – Designed for Primary Care Clinicians

    Patients with cardiovascular diseases and risk factors rely on their primary care providers for optimal care and management of their condition. Learn how to improve the care of your patients with cardiovascular disease and earn credits on demand with one of our free cardiology CME courses.

    See full details chevron_right
    • Cost: Free
    • Credit hours: Varies by Course
    • CME credits awarded by: pmiCME, the accredited division of Pri-Med®
    • Format: On-Demand Courses Online
    • Material last updated: Continuously Updated
    • Expiration of CME credit: Varies by Course
  • FREE

    ScientiaCME Cardiology/Pulmonology

    ScientiaCME Cardiology/Pulmonology has two courses at this time:

    In order to get credit from ScientiaCME, you must first establish a username and password.

    Target Audience: Physicians specializing in Cardiology, Chest Medicine, Family Medicine, Internal Medicine.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    CME: Fabry disease: Updates from recent research findings

    Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.

    After completing this course, physicians will better be able to:

    • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
    • Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
    • Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
    • Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium

    Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 6/25/19
    • Expiration of CME credit: 6/25/21
  • FREE

    Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies

    Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils.

    After completing Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies physicians will better be able to:

    • Describe the pathophysiology of ATTR such that it might inform treatment mechanisms
    • Describe available therapies used for treatment of ATTR and explain current literature supporting use of those therapies
    • Design and implement an appropriate therapeutic plan for treatment of ATTR
    • Describe future therapies currently being investigated for the treatment of ATTR

    Target Audience: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, nurses, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 28, 2019
    • Expiration of CME credit: March 28, 2021
  • FREE

    Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options

    Familial hypercholesterolemia (FH), also known as type II hyperlipoproteinemia, is an autosomal dominant disorder characterized by elevated plasma LDL-C levels in the absence of hypertriglyceridemia (or if triglycerides are elevated, they are so independently of FH).

    After completing Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options physicians will better be able to:

    • Describe the pathophysiology and genetics of FH such that they might inform treatment mechanisms
    • Describe presently available and emerging treatment options for FH and apply them to patient cases
    • Evaluate a FH treatment plan and suggest modifications for improvement
    • Describe clinical and logistical challenges associated with treating and educating patients with FH

     

    Target Audience: Cardiology and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in cardiology; and any other clinicians with an interest in FH.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 22, 2018
    • Expiration of CME credit: October 22, 2020
  • FREE

    CME: Treatment strategies in Fabry disease

    Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels. A defect in the enzyme alpha galactosidase A results in glycosphingolipid accumulation, ultimately leading to multi-organ dysfunction and the patient’s premature death. Early symptoms, which occur during childhood, involve pain and may include Raynaud phenomenon, paresthesias, and arthralgia in the extremities and proximal limbs, as well as impaired gastrointestinal emptying, resulting in abdominal pain, diarrhea, early satiety, postprandial bloating, nausea, and vomiting. In adulthood, the disease’s impact spreads beyond and begins to affect the cardiac and renal systems.

    By the end of the session the participant will be able to:

    • Describe the importance of quick and accurate Fabry disease diagnosis and treatment.
    • Using established methods, determine likelihood of Fabry disease given a patient case.
    • Appropriately describe available therapies used for treatment of Fabry disease and explain current literature supporting use of those therapies.
    • Design and implement an appropriate therapeutic plan for treatment of Fabry disease.
    • Describe future therapies currently being investigated for the treatment of Fabry disease.

    Target Audience: The following healthcare professionals: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 9/4/19
    • Expiration of CME credit: 9/4/21